NCT04510818 is a Phase 1 clinical trial of Capecitabine, Camrelizumab in Head and Neck Cancer, sponsored by Ruijin Hospital.

Who is sponsoring NCT04510818?

NCT04510818 is sponsored by Ruijin Hospital.

What drugs are being tested in NCT04510818?

Interventions in NCT04510818: Capecitabine, Camrelizumab.

What condition does NCT04510818 study?

NCT04510818 studies Head and Neck Cancer, Esophageal Squamous Cancer.

Is NCT04510818 still recruiting?

NCT04510818 is currently status unknown. Last updated 14 August 2020.

Last reviewed 2020-08-14 · How we verify

NCT04510818

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2)

Status unknown Phase 1 Last updated 14 August 2020

What this trial tests

Phase 1 trial testing Capecitabine, Camrelizumab in Head and Neck Cancer in 20 participants. Status unknown.

Timeline

1 August 2020

Primary endpoint
1 August 2022

1 August 2024

Quick facts

Lead sponsor	Ruijin Hospital
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 August 2020
Primary completion	1 August 2022
Estimated completion	1 August 2024
Sites	1 location across China

Drugs / interventions tested

Capecitabine, Camrelizumab — full drug profile →

Conditions studied

Head and Neck Cancer — all drugs for Head and Neck Cancer →
Esophageal Squamous Cancer — all drugs for Esophageal Squamous Cancer →

Sponsor

Ruijin Hospital

Who can join

18 and older, any sex, with Head and Neck Cancer or Esophageal Squamous Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single center phase 1 trail to observe safety and efficacy of metronomic Capecitabine plus Camrelizumab as second-line regimen to treat head and neck cancer or esophageal squamous cancer patients. This study is one of the cohorts of a multi-cohort trial called Combination of Metronomic Capecitabine with Camrelizumab for treatment of refractory solid tumor (McCrest) trial.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Current state of the art: immunotherapy in esophageal cancer and gastroesophageal junction cancer.
Li N, Sohal D. · · 2023 · cited 22× · PMID 37995002 · DOI 10.1007/s00262-023-03566-5
Lipid metabolism associated with efficacy of metronomic capecitabine and camrelizumab in gastrointestinal cancer: an exploratory clinical trial.
Zhou C, Yin Y, Shangguan C, Wu Q, et al · · 2025 · cited 1× · PMID 41121239 · DOI 10.1186/s12916-025-04377-4

Verify or expand the search:

Other trials of Capecitabine, Camrelizumab

Trials testing the same drug.

NCT04932187 — Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3) · Phase 1 · unknown

Other recruiting trials for Head and Neck Cancer

Currently open trials in the same condition.

NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting

Other Ruijin Hospital trials

Trials by the same sponsor.

NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04510818 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
Last refreshed: 14 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04510818.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing